View Post

Savvy Cooperative: People with metastatic triple-negative breast cancer or their caregivers living in Canada

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Eligibility Criteria: Adult who has been diagnosed with metastatic triple-negative breast cancer living in Canada NOTE: Only patients with verified diagnoses will be considered Resident of Canada Details: Asynchronous workshop, 1 hour per day for 3 days Some participants will be selected for 45-minute follow-up in-depth interviews From home Receive: $300 (USD) for the workshop $75 (USD) for the …

View Post

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

In Clinical Studies News by Barbara Jacoby

By: Rachel Narozniak, MA From: onclive.com For the first time in the therapeutic landscape of metastatic triple-negative breast cancer (mTNBC), treatment options now include an antibody-drug conjugate (ADC). The aggressive subtype is associated with poor prognoses. On April 22, 2020, the FDA granted an accelerated approval to sacituzumab govitecan-hziy (Trodelvy) for adults with mTNBC who have received at least 2 …

View Post

CytoDyn Gains IRB Approval to Start Phase II Basket Trial for Leronlimab

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com CytoDyn said on Friday that it received Institutional Review Board approval to begin its Phase II basket trial for its CCR5 antagonist leronlimab (PRO 140). The Phase II trial will investigate the drug in 22 different solid tumors. The trial will enroll up to 30 patients who are CCR5 positive. The single-arm study is examining …

View Post

CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the injection of the first patient in a Phase 1b/2 clinical protocol with treatment-naïve metastatic triple-negative breast cancer (mTNBC). The treatment of the first patient in mTNBC with leronlimab …

View Post

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy

In Clinical Studies News by Barbara Jacoby

Source: G1 Therapeutics From: globenewswire.com G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at …